Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419470 | 0.86 | ESR1 (0.53) | SMN1; SMN2USP2ALDH1A1HTTPOLB | |
| SCHEMBL4417108 | 0.82 | ALDH1A1 (0.59) | SMN1; SMN2USP2ALDH1A1HTTMAPT | |
| SCHEMBL4422023 | 0.80 | MAPT (0.60) | SMN1; SMN2ALDH1A1HTTPOLBMAPT | |
| SCHEMBL4422476 | 0.79 | HTR7 (0.60) | SMN1; SMN2ALDH1A1POLBMAPTKMT2A | |
| SCHEMBL4417442 | 0.78 | USP2 (0.53) | SMN1; SMN2USP2ALDH1A1HTTPOLB | |
| SCHEMBL9987794 | 0.77 | HTT (0.58) | SMN1; SMN2USP2ALDH1A1HTTPOLB | |
| SCHEMBL4429576 | 0.77 | HTR1A (0.64) | SMN1; SMN2ALDH1A1POLBMAPTKDM4E | |
| SCHEMBL4422252 | 0.76 | MAPT (0.57) | SMN1; SMN2ALDH1A1MAPTKMT2ATSHR | |
| SCHEMBL3301951 | 0.74 | HTT (0.60) | SMN1; SMN2USP2ALDH1A1HTTPOLB | |
| SCHEMBL4419782 | 0.74 | HTT (0.52) | SMN1; SMN2USP2ALDH1A1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | disclosed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | SMN1; SMN2 1442/4885USP2 3594/4885ALDH1A1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.